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Much progress has been made in the global fight against leprosy, as evidenced by 
dramatic declines in prevalence rates in recent years. However, leprosy has proven 
elusive. New case detection rates have remained fairly stable, particularly in 
countries with remaining pockets of high endemicity such as India, Brazil, and 
Indonesia. In 2012, the World Health Organization spearheaded the London 
Declaration, which in part aimed for the goal of interruption of transmission of 
global leprosy by 2020. Aggregating the opinions of experts can supplement existing 
data to help determine the feasibility of reaching the WHO goals. To obtain the 
opinions of experts, a cross-sectional survey was sent requesting experts to give 
probabilistic estimates on the likelihood of achieving leprosy control targets. The 
survey results showed that most experts do not think the 2020 leprosy control 
targets will be met. The majority of experts indicated enhanced case finding as the 
most important measure to undertake to improve leprosy control goal success. The 
collection of expert opinions highlights the need for continued attention on leprosy 
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In 2012, the World Health Organization (WHO) spearheaded the London 
Declaration, which in part aimed for the interruption of transmission and global 
elimination of leprosy by 2020 [1]. The goal of leprosy elimination is not new; 
indeed, since 1991, leprosy has routinely been the target of elimination campaigns 
[2].  
 Leprosy, or (ansen s disease, is a chronic infectious disease caused by 
Mycobacterium leprae [3]. Among communicable diseases, leprosy is a leading cause 
of permanent physical disability [4]. In 1982, the WHO introduced a multidrug 
therapy (MDT) program for leprosy [5]. While the introduction of MDT and active 
leprosy control campaigns markedly reduced global prevalence, leprosy remained 
endemic in a few localized regions [6] 
 
To address the lingering issues preventing elimination, the WHO has routinely 
revised their leprosy control goals in a series of declarations summarized in Table 1 
[7-11]. The latest targets, as stated in the 2012 London Declaration, are that 
Vigorous case-finding and treatment would lead to global interruption of [leprosy] 
transmission by 2020, and reduce grade 2 disabilities in newly detected cases to 
below 1/million at global level  [1]. 
 
Table 1. History of WHO leprosy goals/declarations 
 
WHO Goals/Declarations 
Year Report Goal Key Indicator 
1991 44th World Health Assembly 
(WHA44.9) 
…to attain the global elimination of leprosy as a 
public health problem by the year 2000  
 
Prevalence. Defined elimination as attaining a 
level of prevalence below one case per 10,000 
population at the global level. 
 
2000 The WHO Strategic Plan for 
Leprosy Elimination 2000-2005 
Elimination of leprosy as a public health problem 
in all countries by the year 2005  
 
Prevalence. Defined elimination as attaining a 
level of prevalence below one case per 10,000 
population at the national level. 
 
2005 The Global Strategy for Further 
Reducing the Leprosy Burden 
and Sustaining Leprosy Control 
Activities 2006-2010 
The goal of the Global Strategy is to reduce 
further the burden of leprosy and to provide 
access to quality leprosy control services for all 
affected communities, following the principles of 
equity and justice.  
 
Emphasis on various indicators of progress such 
as new case detection rate, treatment 
completion/cure rate, and continued use of 
prevalence for those countries yet to reach the 
elimination target. 
 
2009 Enhanced Global Strategy for 
Further Reducing the Disease 
Burden Due to Leprosy 2011-
2015 
The goal of the Enhanced Global Strategy is to 
further reduce the disease burden due to leprosy 
and sustain the provision of high-quality leprosy 
services for all affected communities, ensuring 
that the principles of equity and social justice are 
followed.  
 
A target of 35% reduction in G2D in new cases per 
million population from 2011 to 2015 has been 
agreed and can be used to evaluate progress 
towards the longer-term goal of reducing G2D in 
new cases to less than 1 in 1 million at the global 
level by 2020.  
 
2012 London Declaration Vigorous case-finding and treatment would lead 
to global interruption of transmission by 2020, 
and reduce grade 2 disabilities in newly detected 
cases to below 1/million population at global 
level.  
Reduction of grade-2 disabilities in newly 
detected cases to below 1 per million population 
at global level by 2020. 
2013 Bangkok Declaration ...declare that it is time for the leprosy-endemic 
countries, as well as their international and 
national partners, to reaffirm their commitments 
and reinforce their participation towards 
addressing leprosy in order to ensure a leprosy-
free world at the earliest...  
Achieve the global target of reducing the 
occurrence of new cases with visible deformity 
(grade 2 disability) to less than one case per 
million population by the year 2020. 
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Whether or not these goals are attainable remains to be seen [12]. In 2014, a total of 
213,899 new leprosy cases were detected globally, with India, Brazil, and Indonesia 
accounting for almost 75% of the new cases [11]. The relative stabilization of the 
new case detection rate over the past 10 years indicates ongoing transmission [13].  
 
The stabilization of new case detection rates has some people questioning whether 
these objectives will be achieved [14]. Many experts argue that the combination of 
epidemiological and biological evidence suggest the W(O s target may be too 
ambitious to be achieved given the current state of control [2,15,16]. 
 
To our knowledge, no previous research has been conducted on exploring these 
dissonant viewpoints on the feasibility of meeting the 2020 leprosy control targets. 
In light of this gap in the research, the objective was to survey leprosy and disease 
elimination experts (1) to elicit whether they believe the 2020 goals will be met and 
(2) to determine what they believe are the most important measures to implement 




In February 2016, a cross-sectional survey created in Qualtrics was sent to 
professionals with expertise in leprosy, neglected tropical diseases (NTDs), and 
forecasting. In order to survey a broad cross-section of leprosy experts, PubMed was 
searched for articles published in 1995 and later containing the terms leprosy, 
leprae, or Hansen’s disease in the title or abstract. Emails of corresponding authors 
were extracted, with duplicates removed. Similarly, NTD experts were targeted by 
extracting emails from all articles published in PLOS NTD that did not contain the 
leprosy keywords in the title or abstract. Duplicate emails within the NTD email set 
were removed and any emails found in both the NTD and leprosy extractions were 
removed from the NTD email set. Forecasting experts were targeted by extracting 
emails from PubMed articles published in 1995 and later that did not contain the 
leprosy keywords or neglected tropical disease in the title or abstract and contained 
one of the following combinations: 
1. forecast + (influenza or HIV or malaria tuberculosis or measles or ebola) 
2. predict + incidence + (influenza or HIV or malaria tuberculosis or measles 
or ebola) and does not contain predictor 
3. predict + prevalence + (influenza or HIV or malaria tuberculosis or measles 
or ebola) and does not contain predictor 
Duplicate emails within the forecasting expert email set were removed and any 
emails found in the both the forecasting extraction and either the leprosy or NTD 
extractions were removed from the forecasting email set. All emails belonging to 
individuals affiliated with leprosy consortium groups at the Proctor Foundation at 




The 11-item survey consisted of multiple-choice questions, slider bars, and 
forecasting exercises designed to assess expertise and elicit opinions on the 
probability of meeting the 2020 leprosy control goals (all analyzed questions 
included in Tables 2-4). For the purpose of this publication, the forecasting exercises 
at the end of the survey were not analyzed. Leprosy knowledge was determined through response to the expert validation question: Which type of leprosy, 
tuberculoid or lepromatous, is more likely to correspond to paucibacillary leprosy?’. A 
free text comment section was included at the end of the survey to allow 
participants the option of providing additional opinions on the subject of leprosy 
control. The questions were tested internally among a group of infectious disease 
researchers at the University of California, San Francisco (UCSF) and Yale University, and this group s comments on the question format and phrasing were 
integrated into the final survey.  
 After the UCSF )nstitutional Review Board granted the study s exemption of 
approval, the survey was disseminated by email. The email message contained a link 
to the survey and indicated the nature of the survey, that participation was 
voluntary and that responses would be anonymous. The survey links for the three 
groups were varied to allow for between group analyses. The survey was sent to the 
entire group of potential participants and remained open for 12 days. A follow-up 
reminder was sent on day 9. Recipient responses indicating change of email address 
were tracked and survey links were sent to the provided email addresses. The 
survey was programmed to ensure participants could complete the study only once 
by utilizing the Prevent Ballot Box Stuffing  option within the Survey Protection 
section of Qualtrics.  
 
The response rate was calculated with the number of completed surveys as the 
numerator and the denominator as the total number of surveys sent minus the 
emails that bounced back due to invalid email addresses. Completed surveys were 
defined as a participant having completed either the 2020 goal probability slider 
questions or the multiple choice question eliciting the most important policy to 
implement to meet the 2020 goals. Participants were able to opt out of responding 
to any question, and all responses from completed surveys were included in the 
analysis. Missing data were excluded from analyses. 
 
Results were summarized with descriptive univariate analyses using percentages 
for categorical data. Bivariate analyses were conducted using ANOVA (Analysis of 
Variance) tests to compare responses by expertise group and to also compare 
responses by subgroups within the leprosy expert group. Free text comments were 
reviewed by researchers and divided into overarching themes based on topic and 
frequency. All analyses were conducted with SPSS software, version 22 (SPSS Inc, 







The email extraction identified 4,191 unique email addresses. 291 participants 
responded to the survey and 238 did so with complete data. After removing 1,170 
bounce-back dead emails and incorporating 11 new emails sent to updated 
addresses acquired via automatic email response, the response rate was calculated 
at 9.6%. Respondents spent an average of 19 minutes on the survey. 44 participants 
included free text in the optional comment section at the conclusion of the survey.  
 
Table 2 displays the characteristics of the survey respondents by group expertise. 
The majority of participants in each group had earned either an MD 
(leprosy=46.2%, NTD=34.4%, forecasting=42.1%) or PhD (leprosy=58.6%, 
NTD=88.0%, forecasting=73.7%). The majority of leprosy experts worked in lab 
research (35.2%) or as clinicians/medical doctors (36.8%), whereas the majority of 
NTD experts and forecasting experts worked in lab research (NTD=31.0, 
forecasting=21.1%) or as epidemiologists (NTD=34.5%, forecasting=47.4%). More 
leprosy experts (58.9%) endorsed Brazil  or India  as their country of expertise 
than did NTD experts (40.0%) or forecasting experts (28.6%). The vast majority of 
leprosy experts correctly answered the leprosy expertise validation question 
(89.8%), while fewer NTD experts (51.6%) and forecasting experts (42.1%) 
correctly answered the question.  
 
A summary of responses to the question addressing the most important policy to 
better achieve the leprosy control goals is shown in Table 3. In all groups, over half 
of group respondents indicated that enhanced case finding was the most important 
measure to implement (leprosy=55.4%, NTD=65.6%, forecasting=66.7%). Among 
the 11 participants that responded Other , free text comments endorsed expanding 
laboratory-based surveillance and improved diagnostic tools (27.3%), more 
integrated service delivery systems (18.2%), determining the precise mode of 
transmission and reservoir (18.2%), increasing healthcare access in endemic 
communities (18.2%), vaccine development research (9.1%), and a lack of sufficient 
knowledge to comment (9.1%).   
 
Table 4 reveals the mean probabilities for achieving each of the 2020 leprosy 
control goals of global interruption of transmission and reduction of grade-2 
disabilities. The mean probability of achieving the global interruption of 
transmission among the leprosy experts was 34.8%, which was not significantly 
different from the NTD experts (36.0%) and forecasting experts (35.1%) (P=0.928). 
There was a significant difference among group means for the probability of 
achieving the reduction of grade-2 disability goal (P=0.026), with the leprosy 
experts (40.7%) indicating this goal would be less likely to be achieved than the 





Table 2: Characteristics of participants (N = 291)1. 
                                                                        Group 
Variable                                                    Leprosy Experts          NTD Experts         Forecasting Experts 
                          N           %                    N           %                    N          % 
Total emails sent                                  1943                               744                            1504        
Responses                                                       225    (100.0)              38    (100.0)             28     (100.0) 
Responses with complete data2                                   187     (83.1)            32     (84.2)              19      (67.9) 
Country                                     146   (100.0)           26     (100.0)       15      (100.0)  
 Brazil                                     33      (22.6)             3      (11.5)         0         (0.0) 
 India                                     23      (15.8)             0        (0.0)         0         (0.0) 
 Indonesia                             2          (1.4)             0        (0.0)           0         (0.0) 
 Other                                     88      (60.3)           23       (88.5)        15     (100.0)  
Highest degree obtained3                                  186     (100.0)           32      (100.0)        19     (100.0)  
 Bachelor s degree or equivalent              52       (28.0)           12       (37.5)         8       (42.1) 
 Master s in Public (ealth or equivalent                                   27       (14.5)             6       (18.8)         3       (15.8) 
 Other Master s degree or equivalent                                  50       (26.9)           14       (43.8)        10      (52.6) 
 MD                                    86       (46.2)           11       (34.4)         8       (42.1) 
 PhD                                  109       (58.6)           28       (88.0)        14      (73.7) 
 Other                                    23       (12.4)             3         (9.4)         5        (26.3)  
Years of experience                                  187      (100.0)            32     (100.0)       18      (100.0)  
 0-5                                        42        (22.5)             9       (28.1)                6        (33.3)  
 6-10                                    34        (18.2)             9       (28.1)         3        (16.7) 
 11-15                                    35        (18.7)             2        (6.3)         2        (11.1) 
 16-30                                    39        (20.9)             6       (18.8)               7         (38.9) 
 over 30                                    37        (19.8)             6       (18.8)         0          (0.0)  
Area of work                                  182      (100.0)           29     (100.0)       19      (100.0)  
 Lab Research                                   64       (35.2)                 9       (31.0)                 4       (21.1) 
 Clinician/Medical Doctor                                  67       (36.8)             2        (6.9)         1          (5.3) 
 Epidemiologist                                   26       (14.3)             1       (34.5)         9        (47.4) 
 Public health program member                                   7          (3.8)             1        (3.4)         1          (5.3) 
 Activist or advocate                                    3          (1.6)                  0         (0.0)                0           (0.0) 
 Other (but none of the above)                                  15          (8.2)                  4       (13.8)               3         (15.8) 
 None I really know nothing about leprosy                               0          (0.0)             3       (10.3)         1          (5.3)  
Country of Leprosy Expertise                                                    180      (100.0)           25      (100.0)       14     (100.0)  
 Brazil                                   45        (25.0)             5       (20.0)                1          (7.1) 
 India                                   61        (38.9)             5       (20.0)         3        (21.4) 
 Indonesia                                     2          (1.1)             0         (0.0)         0          (0.0) 
 Other                                   72        (40.0)             1        (60.0)       10       (71.4) 
Correctly Answered Expertise Validation                               187      (100.0)           31     (100.0)       19     (100.0) 
 Yes                                 168       (89.8)           16       (51.6)        8         (42.1) 
 No                                    5           (2.7)             6        (19.4)              1           (5.3) 
 ) m not sure                                 14          (7.5)             9        (29.0)       10        (52.6) 
1Note that participants were allowed to opt out of responding to any question, so the total number of responses varies depending on the 
particular question 
2Demographic characteristics and analysis were restricted to those participants that provided complete data 
3Participants were allowed multiple responses. Other  category was open-ended and included responses such as DVM. 
Table 3: Most important policy comparisons by group (N = 233). 
                                                    Group 
Variable                                                    Leprosy Experts          NTD Experts          Forecasting Experts 
                                         N          %            N          %              N          %  
Most important measure to better achieve goals                                           186    (100.0)           29    (100.0)                   18    (100.0)  
     Efforts to reduce stigma                                                         10       (5.4)            1        (3.4)                       2      (11.1) 
     Enhanced case finding                                     103     (55.4)           19     (65.5)                     12     (66.7) 
     Point of care DNA detection probe                                                        11       (5.9)                1        (3.4)              2       (11.1) 
     Specialty leprosy program                                      28      (15.1)            1        (3.4)                       1        (5.6) 
     Treatment of contacts                                       15       (8.1)            2        (6.9)                       1        (5.6) 
     Nothing can be done; leprosy can t be eliminated as a public                        .             1        (3.4)                       0        (0.0) 
          health problem using currently available tools  
     Nothing can be done; leprosy will disappear, but this will take            3        (1.6)            0        (0.0)                       0        (0.0) 
          decades due to nature of disease  
     Other1                                                               7        (3.8)            4       (88.5)                      0        (0.0) 
1Participants only allowed one response. Other  category was open-ended. 
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Table 4: Goal likelihood comparisons by group (N = 222). 
                                                    Group 
Variable                         Leprosy Experts   NTD Experts   Forecasting Experts     P value1 
              (N=174)                (N=31)                   (N=17) 
Global interruption of transmission             
 Mean                34.8%    36.0%                35.1%                    0.928 
 SD                 25.7     27.7                       24.8 
Reduction of grade-2 disabilities 
 Mean                40.7%     52.4%                    52.4%                   0.026 
 SD                 26.9                       26.3                        20.6       









Analysis on goal likelihoods and the most important policy restricted to just the 
leprosy experts is shown in Tables 5 and 6. Overall, goal likelihoods for leprosy 
experts did not vary significantly by demographic characteristics within the leprosy 
expert group, though a few differences were noted (Table 5). Though not significant, 
participants with expertise on leprosy in Brazil indicated lower likelihoods of 
achieving global interruption of transmission (26.1%) than did participants with 
expertise on leprosy in India (39.9%) (P=0.084).  
 
Free text comments were provided by 44 participants at the conclusion of the 
survey, 39 of which came from the leprosy experts. Of the 187 leprosy experts to 
provide complete data, 20.9% included free text comments. Common themes 
accompanied by specific examples are shown in Table 7. Many of the comments 
focused on the forecasting questions and the data comprising these questions. Six 
participants mentioned forecasting new case detection rates is difficult because the 
data is dependent on case finding that can be highly irregular (13.6%). Some 
comments expressed skepticism regarding the data itself, with 9 participants 
mentioning case rates are too low as they are not capturing the large numbers of 
undiagnosed cases (20.5%) and 8 mentioning the influence factors such as political 
pressure can have on underreporting true leprosy incidence (18.2%).  
 7 
 
Aside from the forecasting comments, 12 comments further elucidated specific 
methods to reduce leprosy (27.3%), 7 of which focused on the importance of active 
case finding (15.9%). Comments also centered around governmental issues, with 8 
participants commenting that countries need to make leprosy a priority and the 
need for more funding (18.2%) and 5 comments revealing that political factors such 
as declarations of elimination have in fact hindered leprosy control (11.4%). Six 
participants were concerned of a loss of clinical expertise and ability of clinicians to 
accurately diagnose (13.6%). In addition, 3 participants cited incidence of childhood 
leprosy as evidence of ongoing transmission (6.8%) and 2 comments revealed 
concern about rifampicin resistance and relapse (4.5%). Finally, 2 comments 
expressed displeasure at the survey questions and stated that the present survey 
was of no value (4.5%)  
 
 
Table 5: Leprosy experts  goal likelihood comparisons N=1 1 
                                                             Goal 
Variable                 Global interruption of transmission          Reduction of grade-2 disabilities 
                                              Mean          SD          P value                         Mean           SD         P Value 
Area of work                          0.846                 0.545 
 Lab Research       37.1%         26.5                                       40.6%           28.1 
 Clinician/Medical Doctor      35.6%         25.3                                              44.0%          25.0 
 Epidemiologist       29.9%         28.2                   36.7%           30.5 
 Public health program member       25.1%         21.4                                              23.7%          21.0             
 Activist or advocate                          41.3%          4.2                   54.0%           24.2 
 Other (but none of the above)                          34.9%          25.6                                             38.7%          27.3 
Country of Leprosy Expertise      0.058                 0.113 
 Brazil        26.1%         22.3                                      32.2%           24.0 
 India        39.9%         27.0                   43.7%           27.6 
 Indonesia        57.0%         53.7                   65.0%           35.4 
 Other                36.2%         25.7                                      43.4%           27.9 
Highest degree obtained2      0.207                 0.441 
 Bachelor s degree or equivalent      25.7%         22.5                                      31.1%           24.6 
 Master s in Public (ealth or equivalent       28.6%         24.1                   39.0%           26.5 
 Other Master s degree or equivalent      31.5%         26.3                   37.9%           26.6 
 MD        31.9%         23.9                   40.9%           26.8 
 PhD        31.4%         25.0                   37.9%           27.3 
 Other        42.6%         28.0                                              42.7%           26.6 
Years of experience       0.279                       0.350  
 0-5            35.5%         27.2                                      39.1%            28.1  
 6-10        35.4%         20.8                   45.5%            22.5 
 11-15        37.8%         29.1                   45.8%            26.0 
 16-30        26.5%         21.3                                      34.1%            26.9 
 over 30                           34.8%         25.7                                             39.9%            27.0 
1Note that participants were allowed to opt out of responding to any question, so the total number of responses varies 












Table 6: Leprosy experts  most important policy comparisons N=1 1 
                              Most important measure to better achieve goals 
Variable                                      Efforts to       Enhanced case    Point of care DNA   Specialty leprosy   Treatment Nothing can be done; leprosy can t be       Nothing can be done; leprosy will        Other2                             Total 
        reduce stigma         finding             detection probe             program   of contacts   eliminated as a public health problem using    disappear, but this will take decades  
                                                currently available tools                                     due to nature of disease  
                              N    %          N      %           N      %                N      %         N      %                         N      %                                                N      %                        N     %                    N      
Area of work                   
     Lab Research         1    (1.6)      31  (48.4)     8   (12.5)           12  (18.8)    6     (9.4)                       2    (3.1)                                        0    (0.0)                     4    (6.3)               64 
     Clinician/Medical Doctor        6    (9.0)      36  (53.7)     3    (4.5)             12  (17.9)    3     (4.5)                      3    (4.5)                                        2    (3.0)                     2    (3.0)               67 
     Epidemiologist         3   (11.5)    16  (61.5)     0     (0.0)             3   (11.5)     2     (7.7)                      2    (7.7)                                        0    (0.0)                     0    (0.0)               26 
     Public health program member                      0    (0.0)       4   (57.1)      0    (0.0)             1   (14.3)     1    (14.3)                     0    (0.0)                                        1   (14.3)                    0    (0.0)                7 
     Activist or advocate        0    (0.0)       3 (100.0)     0    (0.0)              0    (0.0)      0     (0.0)                      0    (0.0)                                        0    (0.0)                     0    (0.0)                 3 
     Other (but none of the above)                          0    (0.0)       9   (60.0)     0    (0.0)              0    (0.0)      2    (13.3)                     2   (13.3)                                        0    (0.0)                     2   (13.3)              15 
Country of Leprosy Expertise      
     Brazil          0    (0.0)      23 (51.1)      2   (4.4)               7   (15.6)     8   (17.8)                     3     (6.7)                                        1    (2.2)                     1    (2.2)               45 
     India          7   (11.5)     31 (50.8)      4   (6.6)              9   (14.8)     2     (3.3)                      3     (4.9)                                        1    (1.6)                     4    (6.6)               61 
     Indonesia         1    (0.5)        0   (0.0)       0   (0.0)               0    (0.0)       0    (0.0)                      0     (0.0)                                        0    (0.0)                     1    (0.5)                 2 
     Other                  2    (2.8)       44  (61.1)     5   (6.9)            10  (13.9)     5     (6.9)                      3     (4.2)                                        1    (1.4)                     2    (2.8)               72       
Highest degree obtained3    
     Bachelor s degree or equivalent        2    (3.9)      23  (45.1)      3   (5.9)              6   (11.8)      8   (15.7)                    2     (3.9)                                        3    (5.9)                     3    (5.9)                51 
     Master s in Public (ealth or equivalent        11.1      1   1.       1   .                  1 .          1 .                     0     (0.0)                                        1    (3.7)                     0    (0.0)                27 
     Other Master s degree or equivalent        3    (6.0)      24  (48.0)       3   (6.0)             6   (12.0)      6   (12.0)                    2     (4.0)                                        2    (4.0)                     3    (6.0)                50 
     MD          5    (5.8)       55  (64.0)      2   (2.3)            13  (15.1)      2    (2.3)                     4     (4.7)                                        2    (2.3)                     2    (2.3)                86     
     PhD                                                3    (2.8)       55  (50.5)       8   (7.3)            21 (19.3)      10   (9.2)                   14     (2.8)                                       11  (10.1)                   5    (4.6)              109 
     Other          0    (0.0)      11  (47.8)       3  (13.0)           3   (13.0)       1    (4.3)                     1     (4.3)                                         1   (4.3)                     2    (8.7)                23 
Years of experience        
     0-5              2   (4.8)       22  (52.4)       3   (7.1)             6   (14.3)       5   (11.9)                     3     (7.1)                                        1     (2.4)                    0    (0.0)                42 
     6-10          2   (5.9)       21  (61.8)       1   (2.9)             7    (20.6)      0    (0.0)                       2     (5.9)                                        0     (0.0)                    1    (2.9)                34 
     11-15          1   (2.9)       21  (60.0)       3   (8.6)             3     (8.6)       3    (8.6)                       1     (2.9)                                        1     (2.9)                    2    (5.7)                35 
     16-30          2   (5.1)       20  (51.3)       2   (5.1)             8    (20.5)      4   (10.3)                     1     (2.6)                                        0     (0.0)                    2    (5.1)                39 
     over 30                             3   (8.1)       19  (51.4)        2   (5.4)            4    (10.8)      3    (8.1)                       2     (5.4)                                        1     (2.7)                    3    (8.1)                37 
1Note that participants were allowed to opt out of responding to any question, so the total number of responses varies 
2Participants only allowed one response. Other  category was open-ended and included responses such as improved diagnostic tools. 
3Participants were allowed multiple responses. Other  category was open-ended and included responses such as DVM.
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Table 7: Thematic analysis and examples of free text comment entries (N = 44). 
Theme           Example 
Methods to further reduce leprosy              Regarding required interventions for achieving the NTD 2020 targets for  
                                                                                                          leprosy it should be a combination of active case-finding and preventive MDT         
                                                                                                                                                                      for contacts of MB  Leprosy cases  
Importance of active case finding                                Bottom line, more aggressive case finding and possibly chemoprophylaxis  
                    treatment of household contacts of index cases will be necessary to really  
                                                    bring the worldwide numbers down  
Skepticism regarding leprosy statistics 
          Due to undetected/undiagnosed cases          The official data that we see is based on voluntary reporting. There could be   
                                          many more undetected, untreated cases in the community which will add to  
                          reservoir responsible for the transmission  
          Due to political factors                                                          The statistics obtained by the WHO is only a very broad estimate and country  
                      policies, pressure to reduce leprosy or at least its reported statistics and the   
                      type of surveys greatly influence this number  
Need for additional funding / prioritization of leprosy        Currently, we have to bring the message that LEPROSY IS STILL AMONG US     
                   for endemic countries  
Political impact/interference                                 The concept of elimination of leprosy… has been misinterpreted... The  
                   monitoring programs have been weakened by lack of budget. All because   
             leprosy has been eliminated  
Concern of a lack of clinical expertise              I am also concerned about the loss of expertise on microbiological  





Much controversy exists over the concept and feasibility of leprosy elimination. 
Indeed, unquestionable progress has been made in recent decades as substantially 
fewer cases are reported today than in years past [11]. However, declarations of 
elimination have been followed by epidemiological trends that suggest sustained 
transmission and a relative stabilization of new case detection rates [3,17]. For this 
reason, some experts have expressed the sentiment that the WHO would once again 
need to push back the timeline on leprosy control goals as the stated 2020 goals are 
unlikely to be reached [2,3,15-18].  
 
In our survey, most respondents believed that the 2020 leprosy control targets as 
laid out in the London Declaration were unlikely to be achieved. In total, leprosy 
experts gave the goal of global interruption of transmission a 34.8% probability of 
success and the reduction of grade-2 disabilities goal a 40.7% probability of success. 
The NTD and forecasting experts did not differ significantly from the leprosy experts 
in their probabilities, though they tended to be more optimistic about the likelihood 
of achieving the goals than leprosy experts. 
 
Perhaps more illuminating than the quantitative probabilities recorded in the 
survey were the opinions provided in the end-of-survey free text comment section. 
Numerous participants commented questioning the validity of leprosy statistics 
regarding new case counts. In general, commenters expressed the sentiment that 
leprosy case counts are missing what amounts to a large number of undiagnosed 
cases and, therefore, elimination is less achievable than the data might reveal. This 
sentiment mirrored previous studies that have found that actual leprosy case load 
may be many folds higher than reported in certain areas [19,20]. Additionally, some 
participants cited stabilized or increasing rates of child diagnoses and grade-2 
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disability cases as explanations for why the goals may not be realized.  Previous 
research has shown rates of new cases in children and patients with grade-2 
disabilities have not changed significantly over the years, indicating ongoing 
transmission and inadequacies in surveillance [1,17,21].  
 
Commenters also remarked on the inaccuracy of leprosy case data when accounting 
for irregularities in case detection effort. Some researchers have argued that the 
substantial reduction in global reporting of new leprosy cases witnessed between 
the 1990s and 2000s may be the result of under-detection or changes in reporting 
[16]. When less effort is spent on active case finding, new case detection rates can 
naturally fall [22]. With heightened case finding, evidence exists that shows, given 
the spatial clustering and heterogeneity of leprosy, that in some areas leprosy cases 
might actually be increasing [18].  
 
The importance of case detection in determining the true burden of leprosy incidence was further displayed in the disease elimination experts  responses to the 
question eliciting what they believed was the most important policy to better 
achieve the 2020 leprosy goals. In all three expert groups, over half of the 
participants expressed that enhanced case finding was the most important policy to 
implement to better achieve leprosy control goals. This majority consensus 
recommendation follows previous research indicating that reduction of 
transmission through effective case finding should be a goal [18,21].  
 
Enhanced case finding requires a sustained commitment. In 2013, the 17 nations 
with the highest concentrations of leprosy cases signed the Bangkok Declaration, reaffirming these countries  commitment to anti-leprosy and supporting the need 
for continued attention from a public health standpoint [11]. Many of the survey 
comments focused on the need to prioritize leprosy as a public health issue to 
achieve the 2020 goals.    
 
Expert judgement, while not a substitute for scientific analyses, can still provide 
useful insights, particularly when scientific research is incomplete or ongoing 
[23,24]. Due to the difficulty in accurately determining the burden of leprosy, expert 
opinion can provide an additional perspective on the leprosy landscape.  
 
Strengths of this survey include the diverse sample of participants, with the ability 
to compare the opinions of leprosy experts with those of NTD experts and 
forecasting experts. With an average of 19 minutes spent, the time commitment of 
the participants demonstrates that people took the survey seriously and care 
immensely about the topic at hand. Similarly, the large proportion of participants 
that voluntarily added additional comments at the conclusion of the survey provides 
further evidence that the responses were thoughtful and the questions not taken 
lightly.  
 
This study suffers from several limitations. Notably, the overall response rate was 
below 10%. Thought the low response rate was expected from the broad approach, 
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the ability to generalize from these results is necessarily limited. Additionally, the 
survey was designed to prevent ballot box stuffing, but it is possible that individuals 
circumvented this control and took the study more than once. Given the 
professional nature of the participants, this is somewhat unlikely to have occurred. 
Also, though the majority of publications identified in the search for email extraction 
were in English, it is possible that language was a barrier to completing the survey 




In conclusion, we found that leprosy experts and disease elimination experts do not 
believe we are on track to meet the 2020 leprosy control goals as stated in the 
London Declaration. This opinion is consistent with research evidence showing 
ongoing transmission and a stabilization of new case detection rates. The collection 
of expert opinions highlights the need for continued attention on leprosy from a 
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